Measuring TGF-B levels in the blood can be instrumental in monitoring cancer treatment outcomes. Studies have shown that TGF-B levels can be indicative of treatment efficacy, particularly concerning cryoablation of prostate cancer, where elevated TGF-B levels are associated with a higher risk of recurrence. These findings have prompted the adoption of serial TGF-B level monitoring in clinical practice, providing a valuable marker for evaluating treatment options and potential results.
While commercially available and FDA-approved TGF-B inhibitors are on the horizon, natural alternatives with TGF-B inhibitory properties have shown promise in research. Compounds like Curcumin, Capsaicin, EGCG (found in green tea), Sulforaphane (from broccoli seed extract), Berberine (derived from barberry), and Selenium have demonstrated potential in mitigating TGF-B’s effects. Notably, some caution is advised regarding high doses of EGCG, as they can potentially lead to liver damage. Additionally, Black Cumin Seed oil and Losartan have been highlighted as promising options. This research opens doors to a new era of cancer immunotherapy, where TGF-B receptor inhibitors and natural compounds offer hope for improved cancer treatment options, albeit with further research and clinical trials required for validation.
Reference: Jason R. Williams, 15 Oct 2019, The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients’ Lives, https://williamscancerinstitute.com/the-immunotherapy-revolution